FDA on Monday (Feb. 22) issued two new guidances and updated two existing guidances to guide COVID-19 test, vaccine and therapeutics developers on how to update their products to account for COVID-19 variants. The guidances, which were informed based on past experiences with infectious diseases like influenza and HIV, are part of the agency’s next step in addressing and mitigating the emerging COVID-19 mutations, the agency said. FDA has long prepared for possible variations to the SARS-CoV-2 virus, and it...